DONALD E. WILSON, M.D., F.A.C.P.; JOHN QUERTERMUS, M.D.; MANFRED RAISER, M.D.; JAMES CURRAN; ANDRÉ ROBÉRT, M.D., Ph.D.
WILSON DE, QUERTERMUS J, RAISER M, CURRAN J, ROBÉRT A. Inhibition of Stimulated Gastric Secretion by an Orally Administered Prostaglandin Capsule: A Study in Normal Men. Ann Intern Med. 1976;84:688-691. doi: 10.7326/0003-4819-84-6-688
Download citation file:
Published: Ann Intern Med. 1976;84(6):688-691.
The effect of ingestion of a gelatin capsule containing 127 µg of 16,16-dimethyl prostaglandin E2 (DM-prostaglandin E2) or a liquid containing 127 µg of DM-prostaglandin E2 on stimulated gastric secretion in man was studied. DM-prostaglandin E2 significantly reduced the volume, acid concentration, and total acid output of gastric secretion. Secretory inhibition during the 3 h after treatment with the capsule was 37% (volume), 39% (acid concentration), and 60% (acid output). The DM-prostaglandin E2 capsule was nearly as effective as an equivalent amount of DM-prostaglandin E2 in solution. Prostaglandin analogues, because of their oral effectiveness and duration of action, may have therapeutic value in peptic ulcer disease.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Peptic Disease, Peptic Ulcer.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only